
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BOL-DP-o-04
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Recipient : Kindeva Drug Delivery
Deal Size : Undisclosed
Deal Type : Agreement
Kindeva and BOL Pharma Sign Agreement for Development of Inhaled Cannabinoid Products
Details : Under the agreement, Kindeva will develop novel formulations of BOL Pharma’s cannabinoid based drug products delivered by Kindeva’s metered-dose inhaler (MDI) technology.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 01, 2020
Lead Product(s) : BOL-DP-o-04
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Recipient : Kindeva Drug Delivery
Deal Size : Undisclosed
Deal Type : Agreement
